glp-1 agonist and heart failure Glucagon-like peptide 1 receptor agonists: cardiovascular benefits mechanisms of action SGLTi and GLP-1 in HF
Description
Wewer AlbrechtsenNJ
In the 2023 guidelines, the ADA emphasizes both supporting higher weight loss and focusing on obesity as a chronic disease
This bone loss exceeds what can be attributed solely to the substantial weight reduction associated with RYGB
Xiaoyue Zhang contributed to investigation, writing - review & editing, and visualization
Pathway key points: GLP-1RA therapy is used within a defined preconception optimization window
